Australian pharma heavyweight CSL inks deal to manufacture COVID vaccine

Australian pharma heavyweight CSL inks deal to manufacture COVID vaccine
Spread the love

Discovering and trialling a new vaccine is generally a long and exhausive process with a great deal of oversight and regulatory governance. The COVID19 pandemic has fast-tracked the vaccine trialling process like never before and CSL is equipping itself to manufacture more than 80 million doses of the COVID vaccine for Australians. Elysse spoke to Andrew Nash, Senior Vice President of Research at CSL, to find out more about the arrival of the world’s most anticipated and vaccine.



Original Article and Author

Please follow and like us:
editor

editor

Live Updates COVID-19 CASES
RSS
Follow by Email